Showing 11-20 of 32 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Subcutaneous In Vivo Engraftment and Vascularization of 3D Bioprinted Pancreatic-Like Tissue | FluidForm Bio | Adam Feinberg | Cures | 23-December-2025 to 12-June-2026 | $228,696.00 |
| GNTI-122 for the treatment of recently diagnosed type 1 diabetes | GentiBio | Mark Bach | Cures | 01-December-2025 to 30-November-2027 | $4,000,000.00 |
| Advanced Oxygen Generator for Oxygenated Cell Capsules | Giner, Inc. | Linda Tempelman | Cures | 01-June-2021 to 30-September-2026 | $448,173.29 |
| Effectiveness and safety of sotagliflozin in slowing kidney function decline in persons with type 1 diabetes and moderate to severe diabetic kidney disease: The SUGARNSALT Trial | Joslin Diabetes Center Inc. | Alessandro Doria | Improving Lives | 01-January-2024 to 31-December-2028 | $8,913,450.00 |
| Study of ALDH3B2 as a regulator of pancreatic beta cell neogenesis | Joslin Diabetes Center Inc. | Jian Li | Cures | 01-August-2023 to 31-July-2026 | $212,708.89 |
| Validation of a new approach for cardiovascular disease risk stratification and therapeutic targeting in T1D | Joslin Diabetes Center Inc. | Myra Lipes | Improving Lives | 01-September-2023 to 30-June-2027 | $1,341,376.33 |
| Harnessing insulin signaling in β-cells to counter type 1 diabetes | Joslin Diabetes Center Inc. | Namrata Shukla | Cures | 01-March-2024 to 28-February-2027 | $228,995.00 |
| Targeting RNLS for Type 1 Diabetes Therapy | Joslin Diabetes Center Inc. | Peng Yi | Cures | 01-June-2025 to 31-May-2028 | $1,349,997.00 |
| Evaluating the dose and toxicity of telaprevir in a rat model of T1D | Joslin Diabetes Center Inc. | Rohit Kulkarni | Cures | 01-June-2022 to 31-December-2025 | $494,000.00 |
| Innovation Partnership | LabCentral | Luke Wallrich | Cures | 07-July-2025 to 31-May-2026 | $200,000.00 |